Myeloma


What is myeloma?



Myeloma is a type of blood cancer affecting white blood cells called plasma cells. It causes plasma cells to produce too many abnormal antibodies that cannot fight infection. Myeloma is often referred to as multiple myeloma because the bone marrow is usually affected in multiple places around the body.1



Around people are diagnosed with **myeloma** each $year (2017 - 2019)^2$



Myeloma accounts for of blood

cancers

It mainly affects people over the age of

Risk factors

It is not known exactly what causes myeloma, but factors considered to increase a person's risk include1:



Age



Sex



Family history



Ethnicity

Signs and symptoms

People with myeloma may experience a range of symptoms which can impact their quality of life. These may include4:





Kidney damage





Treatment options

Myeloma is a relapsing-remitting cancer, meaning there are periods where myeloma causes symptoms and needs to be treated and periods of remission where it does not require treatment.3 Treatment options include⁵:





Other targeted drugs



Stem cell transplant





antibodies)



Inhibitors (cancer growth blockers)

1. Blood Cancer UK. Myeloma. Available at: https://bloodcancer.org.uk/understanding-blood-cancer/myeloma/. Last accessed: March 2025. 2. Cancer Research UK. $Myeloma\ statistics.\ Available\ at:\ https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma\#heading-Zero.\ Last$ accessed: March 2025. 3. Myeloma UK. What is myeloma?. Available at: https://myeloma.org.uk/understanding-myeloma/what-is-myeloma/. Last accessed: March 2025. 4. Myeloma UK. Symptoms and Complications. Available at: https://www.myeloma.org.uk/understanding-myeloma/symptoms-and-complications/. Last accessed: March 2025. 5. Blood Cancer UK. Myeloma treatment and side effects. Available at: https://bloodcancer.org.uk/understanding-blood-cancer/myeloma/myeloma-treatment-side-effects/myeloma-treatment-aims-types/#treatment-types.Last accessed: March 2025.